<DOC>
	<DOCNO>NCT00197418</DOCNO>
	<brief_summary>Proton pump inhibitor ( PPIs ) mainly metabolize liver CYP2C19 , one cytochrome P450 isoenzymes , show genetic polymorphism associate enzyme activity . The essential role PPI H. pylorus eradication therapy make antibiotic stable bioavailable stomach raise intragastric pH neutral level . Most patient fail eradication H. pylori infection triple therapy PPI , amoxicillin ( AMPC ) clarithromycin ( CAM ) standard dose extensive metabolizer ( EM ) genotypes CYP2C19 and/or infect CAM-resistant strain H. pylorus . Four-times daily dose PPI could achieve complete gastric acid inhibition . Dual therapy 4-times daily dose PPI AMPC could yield sufficient re-eradication rate patient EM genotype CYP2C19 . Metronidazole ( MNZ ) -based re-eradication therapy , triple PPI/AMPC/MNZ therapy , also achieve high eradication rate recommend second line therapy Japan . But carcinogenic action MNZ unclear . The purpose study compare re-eradication rate H. pylori infection dual high-dose PPI/AMPC therapy triple PPI/AMPC/MNZ therapy , validate efficacy re-eradication regimen second line eradication therapy .</brief_summary>
	<brief_title>Second Line Therapy Cure Helicobacter Pylori ( H. Pylori ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patients H. pylori infection Patients without H. pylorus infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>H. pylori infection</keyword>
</DOC>